1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Addressing The Backlog: Government Shutdown Ends, Now FDA Has To Catch Up

After the two-week shutdown, FDA staff are facing a backlog of fiscal year 2014 device submissions. The agency says it is working on a plan and assessing its ability to meet its MDUFA III commitments. The bigger concern, however, may be the regulatory uncertainty created by the short-term deal in Congress.

Furloughed FDA staff have returned to work after the two-week government shutdown to face a backlog of submissions. Some in industry are anxious to hear how the agency plans to deal with the situation, particularly how the backlog will impact its ability to meet user-fee performance goals.

During the 16-day-long government shutdown, the agency continued to review device submissions made by companies prior to Oct. 1, with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Under Pressure: How To Safeguard The EU Responsible Person

 
• By Amanda Maxwell

The roles and responsibilities of EU medtech’s persons responsible for regulatory compliance vary widely in role and risk exposure. The recent TEAM-PRRC meeting highlighted how vulnerable they can be and the steps to protect themselves.

Number of Persons Responsible For Regulatory Compliance Grows Nearly 10%

 
• By Amanda Maxwell

The EU’s Medical Device and IVD Regulations require every manufacturer and authorized representative to have a PRRC. As compliance becomes mandatory for increasing numbers of manufacturers, figures are soaring and this role is becoming both increasingly distinctive and more complex.

Italy’s Responsible Person Sanctions Approach Raises Eyebrows

 
• By Amanda Maxwell

Fines are a fact of life when it comes to manufacturers’ compliance with EU rules on persons responsible for regulatory compliance. But Italy’s stance adds pressure on individuals appointed to the role.

A Trillion On The Table. Addressing Disparities In Women’s Health Isn’t Just Right. It’s Smart.

 
• By Brian Bossetta

Advocates spanning the spectrum of women’s health met in Manhattan to discuss the gender disparities that remain in healthcare and how public policy can correct them and the enormous ROI investors in women’s health can potentially reap.

More from Policy & Regulation

Smaller Companies Next Frontier for FDA’s Voluntary Improvement Program

 
• By Elizabeth Orr

At the Medical Device Innovation Consortium summit, Cogmedix's Scott Cook discussed the challenges and benefits of transitioning to the FDA's Voluntary Improvement Program, which promotes honesty and opportunities for improvement, leading to faster market access and cost savings.

Italy’s Responsible Person Sanctions Approach Raises Eyebrows

 
• By Amanda Maxwell

Fines are a fact of life when it comes to manufacturers’ compliance with EU rules on persons responsible for regulatory compliance. But Italy’s stance adds pressure on individuals appointed to the role.

A Trillion On The Table. Addressing Disparities In Women’s Health Isn’t Just Right. It’s Smart.

 
• By Brian Bossetta

Advocates spanning the spectrum of women’s health met in Manhattan to discuss the gender disparities that remain in healthcare and how public policy can correct them and the enormous ROI investors in women’s health can potentially reap.